Halozyme Therapeutics (HALO) closed at $102.98 on November 10, 2026, up 0.1% from the previous close, on volume of 1,837,121 shares (30-day average 2,361,375).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 5, 2026 | Call Spread | 20-Nov-26130 : 140 C | 3,774 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Halozyme dips as Leerink downgrades on “marginal” Q3 upside
Seeking Alpha News (Fri, 6-Nov 11:13 AM ET)
PRNewswire (Fri, 6-Nov 10:05 AM ET)
PRNewswire (Fri, 6-Nov 9:57 AM ET)
TipRanks (Fri, 6-Nov 7:50 AM ET)
At a glance: stocks gapping down premarket
Seeking Alpha News (Fri, 6-Nov 6:54 AM ET)
Halozyme Therapeutics Non-GAAP EPS of $2.39 beats by $0.03, revenue of $493M beats by $1.44M
Seeking Alpha News (Thu, 5-Nov 4:08 PM ET)
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
PRNewswire (Thu, 5-Nov 4:05 PM ET)
Halozyme to Report Third Quarter 2026 Financial and Operating Results
PRNewswire (Thu, 22-Oct 8:30 AM ET)
PRNewswire (Wed, 7-Oct 8:30 AM ET)
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Halozyme Therapeutics trades on the NASDAQ stock market under the symbol HALO.
As of November 10, 2026, HALO stock price climbed to $102.98 with 1,837,121 million shares trading.
HALO has a beta of 0.74, meaning it tends to be less sensitive to market movements. HALO has a correlation of 0.04 to the broad based SPY ETF.
HALO has a market cap of $11.74 billion. This is considered a Large Cap stock.
Last quarter Halozyme Therapeutics reported $493 million in Revenue and $2.39 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.07.
In the last 3 years, HALO traded as high as $134.00 and as low as $33.15.
The top ETF exchange traded funds that HALO belongs to (by Net Assets): IJH, VTI, VB, VBK, XBI.
HALO has outperformed the market in the last year with a return of +50.9%, while the SPY ETF gained +12.9%. In the last 3 month period, HALO beat the market returning -0.1%, while SPY returned -2.8%. However, in the most recent 2 weeks HALO has underperformed the stock market by returning -19.6%, while SPY returned -2.0%.
HALO support price is $100.87 and resistance is $104.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HALO shares will trade within this expected range on the day.
